Loteprednol Offers Relief Of Ocular Allergy Symptoms With Fewer Side Effects
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Loteprednol Offers Relief Of Ocular Allergy Symptoms With Fewer Side Effects

SAN FRANCISCO, CA. -- February 19, 1999 -- Results of a recently published study show seasonal allergy sufferers may have another option to taking traditional corticosteroid drugs used to relieve the redness, itching and swelling of the eyes.

Corticosteroids such as fluorometholone or prednisolone are effective in treating eye problems experienced by seasonal allergy sufferers. However, drugs derived from the steroid, cortisone, can increase pressure inside the eye, possibly leading to optic nerve damage.

A study published in the American Academy of Ophthalmology’s Journal, Ophthalmology, showed loteprednol etabonate, the first site-active corticosteroid, to be safe and effective in treating ocular allergy symptoms.

“The advantage of loteprednol etabonate is that it is site-active,” said one of the study’s investigators, David G. Shulman, M.D, of San Antonio, Texas. “This means it is not absorbed into the body and, as a result, does not cause side effects associated with steroids such as increased intraocular pressure. This is particularly good news for people concerned about taking steroid medications, including those suffering from glaucoma.”

Of the 135 patients participating in the six-week study, 67 were given eye drops containing loteprednol etabonate 0.2 percent ophthalmic suspension and 68 received the placebo. The loteprednol etabonate-treated patients experienced significant improvement in their symptoms over the placebo group.

Only one patient each from each group experienced elevated intraocular pressure, far below the 33 to 44 percent of patients taking other corticosteroid drugs.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities